[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Figures that are in a Canadian publication on U.S. pharmaceutical R&D state
that basic research and pre-clinical testing accounted for 47.5%, clinical
for 28.4% and "other" for 24.1% of total R&D. (These figures are from
PhRMA for 1988.) The figures in the DiMasi paper (Journal of Health
Economic 1991;10:107-142), including opportunity costs, are $164.5 million
for preclinical costs and long-term and other animal testing and $66.3
million for clinical testing or 71% for preclinical R&D and 29% for
Can anyone confirm that the PhRMA figures are accurate? What would the
"other" include? Can the PhRMA figures be reconciled with the DiMasi ones?
Thanks for any help.
Joel Lexchin MD
121 Walmer Rd.
CANADA M5R 2X8